Home » Stocks » Landec

Landec Corporation (LNDC)

Stock Price: $10.32 USD 0.03 (0.29%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 301.16M
Revenue (ttm) 587.01M
Net Income (ttm) -23.30M
Shares Out 29.18M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE 43.86
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $10.32
Previous Close $10.29
Change ($) 0.03
Change (%) 0.29%
Day's Open 10.25
Day's Range 9.71 - 10.42
Day's Volume 89,614
52-Week Range 7.48 - 12.46

More Stats

Market Cap 301.16M
Enterprise Value 503.97M
Earnings Date (est) Aug 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 29.18M
Float 22.63M
EPS (basic) -0.79
EPS (diluted) -0.80
FCF / Share -1.27
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.22M
Short Ratio 6.11
Short % of Float 6.16%
Beta 1.03
PE Ratio n/a
Forward PE 43.86
P/FCF Ratio n/a
PS Ratio 0.51
PB Ratio 1.11
Revenue 587.01M
Operating Income -21.74M
Net Income -23.30M
Free Cash Flow -37.02M
Net Cash -202.81M
Net Cash / Share -6.95
Gross Margin 13.80%
Operating Margin -3.70%
Profit Margin -4.00%
FCF Margin -6.31%
ROA -0.71%
ROE -8.76%
ROIC -4.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 5
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$13.40*
(29.84% upside)
Low
11.0
Current: $10.32
High
15.0
Target: 13.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue558524470477539477442318277238
Revenue Growth6.36%11.59%-1.5%-11.56%13.1%7.95%39.1%14.75%16.16%-
Gross Profit81.0078.3479.2166.7865.4162.5662.7652.1446.7033.77
Operating Income5.4813.5914.67-20.6318.4620.1924.8714.588.037.98
Net Income0.4124.8310.59-11.6413.5419.1522.5912.703.923.98
Shares Outstanding28.3627.5427.2827.0426.8826.6325.8325.8526.4026.38
Earnings Per Share0.010.890.38-0.430.500.710.850.490.150.15
EPS Growth-98.88%134.21%---29.58%-16.47%73.47%226.67%0%-
Operating Cash Flow16.0219.7829.8420.7626.6221.0521.2322.1814.477.48
Capital Expenditures-44.47-33.49-22.92-39.57-16.44-14.89-8.88-5.37-6.68-5.19
Free Cash Flow-28.45-13.716.92-18.8110.186.1612.3516.817.792.29
Cash & Equivalents1.082.906.009.8914.1314.2415.2622.1836.2648.24
Total Debt15372.9453.9761.1542.5234.3744.3158.9819.8323.77
Net Cash / Debt-152-70.04-47.97-51.26-28.39-20.13-29.04-36.8116.4324.47
Assets519405359343346314291278206200
Liabilities24915213013012610911112668.5967.72
Book Value270253227211218203179150136131
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Landec Corporation
Country United States
Employees 736
CEO Albert D. Bolles

Stock Information

Ticker Symbol LNDC
Stock Exchange NASDAQ
Sector Consumer Defensive
Industry Packaged Foods
Unique Identifier NASDAQ: LNDC
IPO Date February 15, 1996

Description

Landec Corporation, together with its subsidiaries, designs, develops, manufactures, and sells differentiated health and wellness products for food and biomaterials markets. It operates through Curation Foods and Lifecore segments. The Curation Foods segment engages in processing, marketing, and selling of vegetable-based salads, and fresh-cut and whole vegetable products primarily under the Eat Smart brand, O branded olive oils and wine vinegars, and Yucatan and Cabo Fresh guacamole and avocado food products, as well as various private labels. It serves retail grocery chains, club stores, and food service operators. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology transfer, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. It sells its products directly to partners in the medical device and pharmaceutical markets. The company was founded in 1986 and is headquartered in Santa Clara, California.